Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib in advanced GIST
NCT03353753Phase 3Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- May 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Started Feb 2018; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03353753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353753.